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322 The Journal of Thoracic and CardioBackground: We analyzed the intermediate experience, survival, and prosthetic
complications of patients who received the Biocor valve, a new-generation porcine
valve, in the mitral position.
Methods: At the University of Padua, between May 1992 and January 2004, 154
consecutive patients (102 female and 52 male patients; mean age, 72.3  6 years;
age range, 37-86 years) received 158 mitral Biocor prostheses (Biocor Industria e
Pesguisa Ltda, Belo Horizonte, Brazil). Thirty-five percent of the patients had
previous mitral operations, 24% had coronary artery bypass grafting, and 34.6% had
other procedures. Median preoperative New York Heart Association class was III.
Echocardiography was performed in 75% of the long-term survivors. Follow-up
included 609.4 patient-years and was 100% complete, with a median time of 4
patient-years (range, 0.02-11.3 years). At 8 years, 20 (14%) of 142 operative
survivors were still at risk.
Results: Early mortality was 13.6%. According to univariate analysis, New York
Heart Association class III to IV, ejection fraction of less than 40%, urgency, male
sex, and coronary artery bypass grafting were significant perioperative risk factors.
Eight- and 10-year actuarial survival was 51.1%  5.6% (40 deaths). Eight-year
actuarial freedom from valve-related death, thromboembolism, anticoagulant-
related hemorrhage, endocarditis, paravalvular leak, and valve-related complica-
tions were 85.2%  5%, 85.7%  4.4%, 92.6%  3.7%, 94.1%  3%, 91.8% 
3%, and 70.2%  5.7%, respectively. Freedom from structural valve deterioration
was 100%. Actual freedom from reoperation was 93.2%  2.2%. By Doppler
echocardiography, the peak and mean transprosthetic gradients were 15 5 mm Hg
and 6.3  3 mm Hg, respectively (mean follow-up, 4.2  2.7 years).
Conclusion: At intermediate follow-up, the Biocor prosthesis in the mitral position
showed excellent results in terms of valve durability when compared with other
second-generation tissue valves.
The major complication of porcine tissue valves is structural valvedeterioration (SVD) aggravated by younger age and mitral position.A delay of this complication with the second-generation tissuevalves has been observed as a result of improved valve engineeringand mitigation of mineralization by an anticalcification treatment.1The Biocor prosthesis (Biocor Industria e Pesguisa Ltda, Belo Hori-
zonte, Brazil) is a porcine valve fixed in glutaraldehyde at low pressure without
anticalcification treatment. The design is aimed to improve tissue durability: 3
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acetyl copolymer stent, and this suture is covered with a
pericardial sheet. The valve has been used in our institution
since 1992.
The aim of this study was to analyze the intermediate
clinical performance, complication rate, and hemodynamic
performance of the Biocor porcine bioprosthesis implanted
in the isolated mitral position.
Patients and Methods
Between May 1992 and January 2004, 274 Biocor valves were
implanted in the mitral position. One hundred fifty-eight were
isolated Biocor mitral prostheses, 59 were double mitral-aortic
Biocor prostheses, and 3 were double mitral-tricuspid Biocor pros-
theses; the remaining valves were mixed with other prostheses or
plastic repairs. We focused on 154 consecutive patients (102
female and 52 male patients; mean age, 72.3  6 years; median
age, 72.6 years; age range, 37-86 years) who underwent 158
isolated mitral heart valve replacements. The analysis was pros-
thesis oriented. Four patients who received a new isolated Biocor
TABLE 1. Demographics
Variables No.
Prostheses/patients 158/154
Age, y (mean  SD [median, range]) 72.3  6 [72.6, 37-86]
Male/female 102 (66%)/52 (34%)
Sinus rhythm 46 (29%)
Atrial fibrillation 102 (64%)
Pacemaker because of heart block 10 (6.5%)
NYHA I–II 44 (28%)
NYHA III–IV 114 (72%)
Degenerative valvular disease 34 (22%)
Ischemic valvular disease 17 (11%)
Previous valvular repair 12 (7.7%)
Rheumatic valve disease 38 (24.5%)
Previous mitral valve replacement 40 (25%)
Active endocarditis 3 (1.8%)
Previous endocarditis 6 (3.8%)
Stroke before the operation 26 (16%)
Mean pulmonary pressure 30 mm Hg 57 (36%)
Left ventricular function 40% 7 (4.4%)
Chronic obstructive pulmonary disease 18 (11%)
Previous heart surgery 60 (38%)
Urgent intervention* 25 (16%)
Associated procedures
Coronary disease 38 (24%)
Tricuspid valve repair 35 (22%)
Internal carotid artery
endarterectomy
4 (2.5%)
Radiofrequency ablation to restore
sinus rhythm
4 (2.5%)
Others 12 (7.6%)
NYHA, New York Heart Association.
*Within 48 hours from hospital admission.valve at reoperation were entered twice in the statistical analysis.
The Journal of ThoraciThe data were prospectively collected. Patients’ demographic data
are detailed in Table 1.
The median New York Heart Association (NYHA) functional
class was III (mean value, 2.5  0.8). Sixty (38%) patients had
previous surgical procedures: mitral valve replacement (40 pa-
tients), mitral valve repair (12 patients), myocardial revasculariza-
tion (5 patients), and other procedures (3 patients). The mean
mitral prosthesis size was 30  1.4 mm (median, 31 mm; range,
27-33 mm). Explanted bioprostheses underwent pathologic exam-
ination.
A paraseptal atrial incision, interrupted sutures, and posterior
chordal preservation were routinely used. Oral anticoagulation
(international normalized ratio, 2.0-3.0) was continued up to the
third postoperative month unless atrial fibrillation or atrioventric-
ular dilatation was present.
Echocardiographic Analysis
Between June 2000 and January 2004, 73 patients (73/97
[75%]) underwent 122 consecutive 2-dimensional echocardio-
grams. Thirty-four patients underwent 2 echocardiograms, 11
patients underwent 3 echocardiograms, and 4 patients under-
went 4 echocardiograms, respectively. The mean echocardio-
graphic follow-up time was 4.2  2.7 years, and the median
was 4.2 years (range, 0.8-10 years). Twenty-five percent of the
echocardiograms were performed within 1.7 years of the oper-
ation, and 25% were performed 5.7 years after the operation.
The simplified Bernoulli equation was used to calculate pres-
sure prosthetic gradients. Left ventricular volumes were calcu-
lated by an ellipsoid biplane area-length method.2 Left ventric-
ular myocardial mass was calculated by multiplying the
myocardial volume by the specific weight of myocardial muscle
TABLE 2. Cause of death
Mode of death No.
Perioperative death:
21 (13.6%) patients
Cardiac related 15 (71%)
Neurologic 1 (5%)
Sepsis 1 (5%)
Other noncardiac 3 (14%)
Respiratory failure 1 (5%)
Late deaths: 40 (30%)
patients (10%
patient-years)*
Cardiac related (4.6%/
patient-year)
28 (70%)
Acute endocarditis (0.16%/
patient-year)
1 (2.5%)
Thromboembolism (0.3%/
patient-year)
2 (5%)
Cerebral hemorrhage (0.3%/
patient-year)
2 (5%)
Gastrointestinal hemorrhage
(0.1%/patient-year)
1 (2.5%)
Unknown (0.1%/patient-
year)
1 (2.5%)
Other noncardiac (0.8%/
patient-year)
5 (12.5%)
*Including perioperative deaths.(1.05 g/mL). The left ventricle was defined as normal when the
c and Cardiovascular Surgery ● Volume 129, Number 2 323
ar a
Surgery for Acquired Cardiovascular Disease Rizzoli et al
A
CDleft ventricular end-diastolic volume was less than 70 mL/m2
and the mass/volume ratio was between 0.8 and 1.2 g/mL. The
ejection fraction (percentage) was calculated as follows: (End-
Figure 1. Eight-ye
TABLE 3. Overall 8-year Kaplan-Meier freedom from valve-
related events*
Actuarial estimate 
SD
Linearized rate (%/
patient-year)  SD
Valve-related death 85.2% 5% 10 0.43
Paravalvular leak 91.8% 3% 1.5 0.52
Reoperation 91.1%  3%
(actual estimate,
93.2%  2.2%)
1.5  0.52
Thromboembolism 85.7% 4.4% 2.0 0.59
Endocarditis 94.1% 3% 0.83 0.37
Major bleeding 92.6% 3.7% 1.11 0.41
Valve-related
complications
70.2% 5.7% 4.6 0.96
*No events recorded beyond 8 years.diastolic volume  End-systolic volume)/End-diastolic volume.
324 The Journal of Thoracic and Cardiovascular Surgery ● FebrPatient Follow-up
The follow-up period, including direct visits, questionnaires, and
telephone interviews, was closed in January 2004, and the cumu-
lative time was 609.4 patient-years; it was 100% complete. Mean
follow-up time was 4.4 0.027 years, and the median was 4 years
(range, 0.02-11.3 years).
Statistical Analysis
The guidelines of Edmunds and colleagues3 for morbidity and
mortality reporting were used for defining postoperative compli-
cations and prosthesis-related events. The linearized rate of post-
operative complications and prosthesis-related events was ex-
pressed as percentage per patient-year. The 2 test was used for
statistical comparison.
Estimate of overall survival was calculated by the Kaplan-
Meier method and expressed as the percentage  SE or the
percentage  95% confidence interval (CI). Fifteen patients were
younger than 65 years of age (Figure E1). No events were recorded
beyond 8 years of follow-up; nonetheless, our report was limited to
8 years, with 20 patients at risk (14% of survivors). Actual com-
plication freedom was calculated by the method of Grunkemeier
ctuarial survival.and associates.4
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Operative Results
Perioperative mortality was 13.6% (95% CI, 5.9%-16%),
affecting 21 patients in 158 operations. The male/female
ratio was 10:11 (mean age, 72.3  1 years; range, 62-78
years). Nineteen (90%) patients were in NYHA class III to
IV, 43% (9/21) had an urgent or emergency operation, 52%
had concomitant procedures (7 CABGs, 2 internal carotid
thromboendarterectomies, and 2 atrial thrombectomies),
33% (7/21) had a previous cardiac operation, and 24%
(5/21) had an ejection fraction of less than 40%.
NYHA status III to IV, low ejection fraction, urgent
operation, male sex, and myocardial revascularization were
identified as significant univariate risk factors (P  .05).
Causes of death are detailed in Table 2.
Survival
Overall survival was 51.1%  5.6% (Figure 1). There
were 40 late deaths: 28 (70%) were cardiac related, and
8 (20%) were exclusively valve related. The survival of
younger patients (65 years) was better than the survival
Figure 2. Eight-year actuaof older patients (65.2% [3 patients at risk] vs 49.4% [17
The Journal of Thoracipatients at risk], P  .4). Actuarial freedom from valve-
related death was 85.2%  5% (linearized rate of 1.0%
per patient-year, Table 3). Causes of late death are de-
tailed in Table 2. At the end of follow-up, mean NYHA
class was 1.97, 82% of patients were receiving antico-
agulants (80/97), and 50% were in sinus rhythm (49/97).
Eighty-four percent of patients in NYHA class III to IV
improved, and 84% of patients in NYHA class I to II
remained in the same class.
Thromboembolism
Twelve major thromboembolic events occurred in 12 pa-
tients, 2 early and 10 late. Among these patients, 25% had
an embolic stroke before the operation; 9 patients had atrial
fibrillation and were given anticoagulant therapy. Embolism
was fatal in 3 patients. Actuarial freedom from thromboem-
bolism was 85.7%  4.4% (Table 3).
Hemorrhagic Events
Seven patients had anticoagulation-related major hemor-
reedom from reoperation.rhage, which was fatal in 3 cases. Actuarial freedom from
c and Cardiovascular Surgery ● Volume 129, Number 2 325
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ble 3).
Paravalvular Leak
Nine patients were affected, and 5 underwent reopera-
tion. Dehiscence was mostly related to previous interven-
tions: SVD (3 patients), percutaneous valvuloplasty (1
patient), and paravalvular leak (1 patient). One patient
had previous endocarditis and one had ischemic valve
Figure 3. Eight-year actual freedom fr
TABLE 4. Echocardiographic data
Valve size No. BSA, m2
P
gradient,
mm Hg
M
gradient,
mm Hg EF, %
29 50 1.6 0.13 16  5 6.7  3 55  10
31 47 1.7 0.16 15  5 6.2  3 51  11
33 25 1.8 0.15 12.6 6 5.4 2.4 53  13
Mean 122 1.7 0.16 15  5 6.3  3 53.6 11
BSA, Body surface area; EF, ejection fraction; M/V, mass/volume; LVEDV
orifice area.disease as predisposing factors. Two further cases oc-
326 The Journal of Thoracic and Cardiovascular Surgery ● Febrcurred in a rheumatic and a dysplastic valve. The median
interval time between implant and paravalvular leak di-
agnosis was 1 year (range, 1.9 months to 5.5 years). An
atrial thrombus was observed in one patient undergoing
reoperation. Actuarial freedom from leak was 91.8% 
3% (Table 3).
Endocarditis
Five patients had endocarditis. Four were medically treated,
operation. Dotted lines depict the CI.
/V ratio,
g/mL
LVEDV,
mL/m2
LAC,
mL/m2
Indexed EOA,
cm2/m2 (no.) EOA, cm2 (no.)
5 0.1 73  23 69 22 1.9 0.64 (31) 3.06 0.88 (31)
5 0.17 77 33 100 63 2.0 0.55 (28) 3.27 1.4 (28)
1  0.19 91 50 91 67 1.8 0.55 (18) 3.63 1.57 (18)
1 0.9 77  33 85 53 1.9 0.58 (77) 3.26 1.23 (77)
ventricular end-diastolic volume; LAC, left atrial chamber; EOA, effectiveM
1.1
1.1
1.1
, leftwith 50% mortality. A single patient underwent reoperation
uary 2005
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carditis was 94.1%  3% at 8 years (Table 3).
SVD
None of the Biocor prostheses implanted in the mitral
position were replaced because of SVD. All the replaced
Biocor prostheses underwent pathologic examination, and
none showed signs of cusp calcification.
Reoperations
Nine patients underwent reoperation: 5 because of pros-
thetic dehiscence, 2 because of disease progression in the
aortic valve, 1 because of acute endocarditis, and 1 because
of atrioventricular pseudoaneurysm. The very late reopera-
tions, after 2.5 and 5.3 years, respectively, were due to
progression of aortic valve disease. The dehiscence-related
reoperations were performed between 1.3 and 1.8 years,
with a single exception (within 2 months). Pseudoaneurysm
was repaired after 10 days, and endocarditis was treated
after 73 days. Actuarial (Table 3) and actual freedom from
reoperation were 91.1% 3% and 93.2% 2.2% (95% CI,
Figure 4. Time-related peak and mean echocardiograp88.8%-97.6%), respectively (Figures 2 and 3).
The Journal of ThoraciValve-Related Complications
Five patients had more complications. There were 28 first
events, including hemorrhage, thromboembolism, endocar-
ditis, paravalvular leak, and reoperation, with the exclusion
of the 2 reoperations resulting from progression of disease
of the aortic valve. Actuarial freedom was 70.2%  5.7%
(Table 3).
Echocardiography
Mean and peak transprosthetic gradients for all valves were
6.3  3 mm Hg and 15  5 mm Hg, respectively. Ejection
fraction, average body surface area, mass/volume ratio, left
ventricular end-diastolic volume, volume of the left atrial
chamber, and effective orifice area are summarized in Table
4. Comparing echocardiographic data of patients with a
valve functioning for more versus less than 6 years, mean
and peak gradients were similar (P  .7). In the 49 patients
who underwent repeated echocardiography, the valves
showed, over time, stable mean and peak transvalvular
gradients (Figure 4). Thirty patients had pulmonary hyper-
gradients in patients with repeated echocardiograms.tension, and the mean value of peak pulmonary artery
c and Cardiovascular Surgery ● Volume 129, Number 2 327
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mild valve incompetence, with a mean value of 1.25  0.6.
Discussion
In the time interval of this study, 253 tissue valves, including
158 Biocor, 18 Biocor Epic, 9 Hancock II, 25 Carpentier-
Edwards Perimount, 20 Labcor, and other prostheses were
implanted in an isolated mitral position. Our indications for the
use of bioprostheses were identical to those reported by the
American Heart Association,5 finally depending on operating
table findings and prosthesis availability.
The purpose of our study was to verify the advantage of
the mitral Biocor prosthesis, monitoring the incidence of
SVD and other prosthesis-related complications. Calcifica-
tion is the main cause of biologic prosthesis dysfunction and
reoperation.6 A less common cause of early structural de-
terioration is commissural dehiscence, which affects mostly
mitral bioprostheses.7
Younger operative age, chronic renal failure, and mitral
position have been identified as independent risk factors for
SVD.8 Therefore, patients older than 65 or 70 years are
usually selected for mitral valve replacement with a tissue
valve because in these patients the valve should function
longer than the expected life.
In 1982, the second-generation porcine bioprosthesis,
including the Carpentier-Edwards supra-annular, Hancock
II, and Biocor prostheses, was introduced on the market,
with the aim to reduce the SVD incidence and to extend the
age range of successful clinical use. Contrary to the Han-
cock II and Carpentier-Edwards prostheses, the Biocor pros-
thesis did not receive an anticalcification treatment. Until
now, long-term results in the isolated mitral position have
been reported by Myken,9 Kirali,10 and their associates.
Clinical Results
Perioperative mortality (13.6%) was related to the advanced
age of our series (median age, 72 years) and to inadequate
risk factor neutralization.8 Thirty-seven percent of our pa-
tients had a previous operation, and 44% had an urgent
operation. Other frequently identified risk factors were older
age, operative era, and NYHA class. On the contrary, the
late survival of our older patients was excellent (51.6%),
and only Kirali and associates10 reported a better overall
long-term survival (77% at 10 years) in a significantly
younger (average, 48 years; P  .0001) patient population.
In our series the mean transprosthetic gradient was 6.3
3 mm Hg, and it was inversely related to prosthesis size.
Thirty-two patients showed mild incompetence. In the pa-
tients who underwent consecutive echocardiography, the
recordings showed hemodynamic stability over time. Un-
fortunately, few articles report sufficient echocardiographic
data on second-generation mitral bioprostheses for compar-
328 The Journal of Thoracic and Cardiovascular Surgery ● Febrison, and reports on time-related changes of the valvular
gradients are missing.
Overall freedom from valve-related complication is sim-
ilar to that obtained with other tissue valves.1,7,11,12
The unique valve-related cause of Biocor reoperation
was paravalvular leak, with an incidence similar to that
observed by Myken and coworkers9 with the same valve.
This complication, which is due to several patient-intrinsic
factors, technical factors, or both, occurred in our series
mostly after reoperation for SVD or prosthetic paravalvular
leak, and therefore we do not think there are enough data to
link it to prosthetic factors.
Freedom from SVD
There were no reoperations because of SVD, and further-
more, no patient showed signs of dysfunction caused by
dystrophic calcification at 2-dimensional echocardiography.
Published experiences with this prosthesis were also satis-
factory. Myken and coworkers9 reported 100% SVD free-
dom in the mitral position at 15 years in patients older than
61 years, and Kirali and colleagues10 reported a 95% free-
dom in patients older than 65 years.
Commissural dehiscence complicated the functioning of
several models of tissue valve,1,7,13,14 occurring mostly in
larger mitral valves being subjected to higher mechanical
stress. This complication was never observed in our ex-
planted Biocor prostheses. We think that the valve design,
protecting the suture of the 3 valve leaflets with a strip of
pericardium, might offer some advantage.
Conclusion
The design-related favorable lack of commissural dehis-
cence and the overall valve-related complication incidence
similar to that of other porcine and pericardial valves of the
last generation make the Biocor valve a reliable choice
when a higher valve stress can be anticipated, as in the
mitral position and in relatively active patients.
We thank Annarita Miola for assistance in preparing the echo-
cardiographic data collection, and Nicola Paccagnella for prepa-
ration of the figures.
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Figure E1. Cumulative age distribution.
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